Healthcare Industry News:  Clindamycin 

Biopharmaceuticals Dermatology

 News Release - March 2, 2006

Obagi Announces Results of Three Clinical Studies on a Novel Benzoyl Peroxide Formulation for the Treatment of Acne

LONG BEACH, Calif.--(HSMN NewsFeed)--March 2, 2006--Obagi Medical Products, Inc. (Obagi) announced today that they will present three clinical posters on a novel Benzoyl Peroxide (BPO) formulation for the treatment of P. Acnes at the 64th annual American Association of Dermatology (AAD) meeting in San Francisco this week. Three separate clinical trials demonstrate the unique properties of a new BPO technology that increases penetration to the infected follicle. These results were achieved through the application of Obagi's Penetrating Therapeutics(TM) technologies to a BPO formulation.

Benzoyl peroxide has been shown to be an effective therapy for acne; however, currently marketed formulations may be limited in their ability to penetrate down to the base of the hair follicle where P. Acne bacteria is most active and problematic in acne skin. In the first study, in-vitro measures of percutaneous absorption demonstrated more than 2 to 3 times more penetration than other formulations with up to 10% BPO. This study compared Obagi's BPO formulated at a 6.25% concentration, to commercially available formulations at 6%, 8% and 10% concentrations.

The second study demonstrated the ability of Obagi's novel formulation of BPO solution to have greater in vivo bactericidal effect throughout a 72 hour period after one single application as compared to both monotherapy and combination therapy BPO products. This study measured bactericidal activity (or P. Acne bacteria kill rates) during the 72 hours after application, comparing Obagi's BPO formulated at 5% versus a commonly prescribed 5% BPO gel, and a 5% BPO/1% Clindamycin combination product.

In the third study, Obagi's BPO solution demonstrated greater in vivo bactericidal effectiveness against both a BPO monotherapy and a BPO combination therapy. This study compared the same formulations used in the 72 hour study, measuring bactericidal activity over a 16 day, daily treatment cycle.

"These results validate our ability to use our Penetrating Therapeutics technology platform to drive greater penetration of an active agent across the skin barrier, generating excellent clinical results," said Steve Carlson, Obagi CEO. "This technology breakthrough represents a new area of therapeutic focus in skin care for Obagi."

The AAD meetings take place March 3rd through March 5th, 2006. Jose Ramirez, Ph.D., of JR Chemical and Judy Hattendorf, Obagi's Senior VP of Product Development, will be available at the poster exhibits #141, 158 and 159 for review and discussion of the study results. Additional information may be obtained at the Obagi booth #1325.

About Obagi Medical Products, Inc.

Obagi, a leader in the physician-dispensed skin care channel, develops and commercializes skin health products for the dermatology, plastic surgery and related Aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi's products are designed to improve penetration of agents across the skin barrier common and visible skin conditions in adult skin such as chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi launched its first skincare system, Obagi Nu-Derm, in 1988; and in 2004 launched the first and only prescription strength Vitamin C and hydroquinone system, Obagi-C Rx. Obagi System products are only available through physicians. Visit www.obagi.com for information.


Source: Obagi Medical Products

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.